Vancouver, September 19, 2007 - Zecotek Medical Systems Inc. (TSX-V: ZMS; Frankfurt: W1I) today announced it has initiated commercial production of its new-generation CW single-frequency Ti:Sapphire laser, model TIS-SF-787. The latest product in Zecotek’s line of lasers, the TIS-SF-787 offers an ultra-narrow linewidth which, together with its super-wide tunable range, new level of compactness and frequency-stability, position the laser to be best-in-class in the growing laser market.

“Our new ring Ti:Sapphire laser combines excellent reliability and the best available radiation frequency stability, with a traditional super-wide tunable range ”, said Dr. A. F. Zerrouk, Chairman, President, and CEO of Zecotek . “The TIS-SF-787 model also allows for key operational regimes to be activated in hands-free mode, therefore considerably improving the user experience and making possible the automation of tuning procedures and smooth frequency scanning.”

Existing Ti:Sapphire lasers are limited to a laser line width of 50-100 kHz. Zecotek’s TIS-SF-787 laser has an ultra-narrow linewidth at less than 10kHz, expanding the market for new applications in fundamental research (atomic cooling, atomic trapping and quantum manipulation, optical pumping), contemporary cutting-edge technologies (atomic lithography, optical metrology, high-density data recording) as well as microelectronic/ nanofabrication technologies including state-of-the-art atom-optical techniques, such as direct-write atom lithography for the production of enhanced nanostructures and unique atomic patterns.

The TIS-SF-787 laser also features an exceptional wavelength range, from 690 to 1000 nm, which can be expanded into the short-wavelength 345–500 nm domain using Zecotek’s existing resonant frequency doubler. In this configuration the radiation line width remains less than 10 kHz for the fundamental radiation and less 20 kHz for the second-harmonic radiation.
Other features include:

• High generation efficiency. Zecotek’s TIS-SF-787 laser has high generation efficiency with output power reaching up to 2/3.8 W with pump radiation power of 10/18 W.
  
• Small form factor. Ti:Sapphire lasers are typically ‘pumped’ by powerful DPSS lasers. The small dimensions of the Zecotek TIS-SF-787 model represent an alternative to existing configurations. It offers the end users greater convenience and space saving and is designed to enhance its use in laboratory and manufacturing environments.
  
• Efficient control system. The electronic control system of Zecotek’s TIS-SF-787 model has a wide range of convenient and interactive control options. An exclusive feature is the Smart-Relock function that allows reliable and uninterrupted frequency stabilisation of the laser even under considerable ambient disturbances. The laser is offered with a number of options, including stabilisation to an atomic resonance, computer-controlled interface, and OEM versions for special applications.

The company is currently taking orders for shipment to customers for January 2008. The TIS-SF-787 model will be manufactured for Zecotek under contract with its associate company, Tekhnoscan Lasers of Novosibirsk, Russia, and distributed under the Zecotek trademark through Zecotek Laser Systems Pte Ltd., the company’s wholly owned subsidiary. The company anticipates that with its improved performance and cost parameters, the TIS-SF-787 model has the potential to capture significant market share of the growing demand for Ti:Sapphire lasers in the biotechnology, superconductivity and nanotechnology industries.

– 30 –

About Zecotek
Zecotek Medical Systems (TSX-V: ZMS; Frankfurt: W1I) is a bio-photonics technology company developing high-performance crystals, photo detectors, medical lasers, optical imaging and 3D display technologies for commercial applications in the medical diagnostics and high-tech industry. Founded in 2003, the company has three distinct operating divisions: medical imaging, medical lasers and 3D display and labs located in Canada, Singapore and Russia. Zecotek commercializes its novel, patented and patent-pending bio-photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders.


This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

For additional information on Zecotek Medical Systems and our technologies please see our website at www.zecotek.com.

For additional information please contact:
Zecotek Medical Systems, Inc.
MICHAEL MINDER
CFO; VP Corporate Development
T: (604) 827-5203

Caliber Capital Partners
TIM MCNULTY
T: (778) 327-6678
E: ir@zecotek.com

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotekmed.com.